Enanta Pharmaceuticals, Inc (ENTA) is a publicly traded Healthcare sector company. As of May 21, 2026, ENTA trades at $9.48 with a market cap of $391.10M and a P/E ratio of -5.28. ENTA moved -0.87% today. Year to date, ENTA is -2.16%; over the trailing twelve months it is +124.22%. Its 52-week range spans $4.09 to $17.15. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces ENTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Enanta Pharmaceuticals Posts Q2 Loss of $0.45, Shares Jump 5.3%: Enanta reported a fiscal Q2 net loss of $0.45 per share for the quarter ended March 31, 2026, compared with a $1.06 loss a year earlier and marginally missing the consensus loss estimate of $0.46. Revenue also fell short of analyst forecasts, triggering a 5.3% share rally post-release.
| Metric | Value |
|---|---|
| Price | $9.48 |
| Market Cap | $391.10M |
| P/E Ratio | -5.28 |
| EPS | $-2.60 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.15 |
| 52-Week Low | $4.09 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $69.21M |
| Net Income | $-61.98M |
| Gross Margin | 0.00% |
3 analysts cover ENTA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.